Scleroderma

Current Location

39 Scleroderma Trials Near You

Power is an online platform that helps thousands of Scleroderma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Nivolumab for Cancer

Columbus, Ohio
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

300 Participants Needed

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.

Trial Details

Trial Status:Active Not Recruiting

301 Participants Needed

This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

48 Participants Needed

This trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

144 Participants Needed

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:21+

1092 Participants Needed

This trial is testing anifrolumab, an injectable medication, in adults with systemic sclerosis. The goal is to see if it can reduce immune system attacks to lessen symptoms and prevent further damage. Anifrolumab is a human monoclonal antibody that targets the type I interferon receptor and has been tested in multiple studies for systemic lupus erythematosus (SLE) and other autoimmune diseases.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

306 Participants Needed

This trial is testing a medicine called Avenciguat to see if it helps adults with a condition called scleroderma, which affects the skin and internal organs. Participants take the medicine for several months. The study checks if the medicine improves lung function and other symptoms.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

188 Participants Needed

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

300 Participants Needed

This trial tests a new medication called tulisokibart on people with a lung disease called SSc-ILD. The goal is to see if it is safe and helps improve their condition.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

152 Participants Needed

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

400 Participants Needed

This trial is testing a new drug called efzofitimod to see if it can help people with a lung disease linked to systemic sclerosis. The goal is to find out if the drug can improve their breathing and skin health.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

25 Participants Needed

This trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

320 Participants Needed

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being. The study team hypothesize that participants that receive the intervention will have better improvements immediately after treatment at week 8 in all cognitive function measures, non-cognitive symptoms, and self-management compared to those in the waitlist control.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

66 Participants Needed

The purpose of this pilot study is to explore the use of a large language model (LLM) in providing education and behavioral health coaching for individuals with Systemic Sclerosis (SSc). The goal of the LLM is to help user set or modify behavioral goals, provide education, or emotional support as needed by the participant. The primary outcome for this study is to assess the feasibility and acceptability of using an AI-supported health coaching tool over a four-week period.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

20 Participants Needed

Tibulizumab for Scleroderma

Ann Arbor, Michigan
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

80 Participants Needed

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

86 Participants Needed

CABA-201 for Scleroderma

Ann Arbor, Michigan
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

12 Participants Needed

HZN-825 for Scleroderma

Ann Arbor, Michigan
This trial tests HZN-825, a medication, in people with diffuse cutaneous systemic sclerosis. It aims to see if the drug can improve lung function and overall health by affecting the disease process.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation

240 Participants Needed

TENS for Scleroderma

Ann Arbor, Michigan
The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma. Participants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

16 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Apollo Device for Scleroderma

Pittsburgh, Pennsylvania
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

160 Participants Needed

Efgartigimod for Scleroderma

Ann Arbor, Michigan
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

81 Participants Needed

Sodium Thiosulfate for Calcinosis

Pittsburgh, Pennsylvania
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

20 Participants Needed

This is an open-label, multi-center, multi-cohort, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with Immune-Mediated Diseases (IMD) including systemic sclerosis \[SSc\], idiopathic inflammatory myopathies \[IIM\], and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis \[AAV\].
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

72 Participants Needed

Stem Cell Transplant for Scleroderma

Pittsburgh, Pennsylvania
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:8 - 60

8 Participants Needed

The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

11 Participants Needed

This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

15 Participants Needed

This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

45 Participants Needed

CTX112 for Lupus

Chicago, Illinois
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

80 Participants Needed

CNTY-101 for Lupus

Chicago, Illinois
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:17+

48 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Scleroderma clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Scleroderma clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Scleroderma trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Scleroderma is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Scleroderma medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Scleroderma clinical trials?

Most recently, we added Stem Cell Transplant for Autoimmune Diseases, Extracorporeal Photopheresis for Systemic Sclerosis and AlloNK + Rituximab for Rheumatic Diseases to the Power online platform.

Is there hope for scleroderma?

Yes—although scleroderma still has no one-shot cure, survival and quality of life have improved dramatically thanks to earlier organ screening, targeted drugs that slow lung and skin damage, and even stem-cell transplants for the most aggressive cases. Prognosis varies by subtype, but many people—especially with limited disease—now live full lifespans when they partner with a rheumatology team, stay vigilant for lung or heart changes, and tap into clinical trials and support resources. In short, progress is real and ongoing, so there truly is hope.

What is the best hospital in the US for scleroderma?

No agency publishes an official “#1 hospital” for scleroderma, so experts judge centers by patient volume, multidisciplinary specialists, active clinical trials, and research output. Programs that consistently meet those benchmarks include Johns Hopkins (MD), University of Pittsburgh Medical Center (PA), Hospital for Special Surgery/Columbia (NY), Stanford (CA), Mayo Clinic (MN), Cleveland Clinic (OH), and Brigham and Women’s (MA). Ask any prospective center about how many scleroderma patients it sees each year, what organ-specific teams and trials are available, and whether telehealth or second-opinion services fit your insurance and travel limits.

What triggers scleroderma?

Scleroderma starts when a person who already carries several “risk” genes experiences an additional hit—most convincingly long-term exposure to silica dust or strong organic solvents, certain chemotherapy drugs (e.g., bleomycin), or, in a minority, an immune reaction linked to a recent cancer or infection. These triggers injure the small blood-vessel lining, the immune system over-reacts, and excess collagen is laid down, thickening skin and sometimes organs; however, in many patients no definite trigger is ever found, which is why avoiding heavy chemical exposure and staying up-to-date with routine health checks is wise but cannot fully prevent the disease.

What would you not recommend for a patient with scleroderma?

Think “anything that injures fragile skin, clamps down blood flow, or stresses the kidneys”—those are the main things to avoid in scleroderma. That means skipping tattoos or piercings; quitting smoking, vaping, or other nicotine; keeping fingers warm and steering clear of cold aisles or ice water; and avoiding medicines that tighten blood vessels (certain decongestants, non-selective beta-blockers, migraine ergot/triptan drugs) or high-dose steroids and other kidney-toxic drugs unless your specialist says otherwise. Review every new procedure or medication with your rheumatologist so safer substitutes or protections can be arranged.

How much does it cost to treat scleroderma?

Treating scleroderma can run anywhere from about US $10–25 k per year for milder cases that need mainly clinic visits, routine tests and inexpensive medicines, to well over US $50 k—and sometimes above US $100 k—when lung or heart complications require drugs like nintedanib, bosentan or prostacyclin infusions, frequent hospital stays, or stem-cell transplant. The number you personally face depends far more on disease severity and insurance coverage than on any single “sticker price,” so the smartest move is to have your care team outline the expected treatments up front and, at the same time, apply for insurer pre-authorisation and drug-company or charity copay programs that can slash out-of-pocket costs.

Is scleroderma worse than rheumatoid arthritis?

It depends on what you mean by “worse.” Systemic scleroderma is rarer but more life-threatening because it can scar internal organs; even with modern care, about 15–30 % of patients die within 10 years. Rheumatoid arthritis is less deadly but far more common and can severely damage joints and raise heart-disease risk if untreated. In short, scleroderma carries the higher risk of early death, while rheumatoid arthritis more often causes long-term disability—early diagnosis and aggressive treatment are crucial for both.

What is a good supplement for scleroderma?

Start by correcting any lab-proven deficiencies—vitamin D is low in many people with scleroderma, so your doctor may suggest 800–2,000 IU (or the dose needed to reach normal blood levels). After that, the best-studied add-ons are marine fish-oil (about 1–3 g EPA + DHA daily) and N-acetyl-cysteine, which small studies suggest can ease Raynaud’s attacks and digital ulcers; high-dose iron or vitamin A should be avoided unless you are clearly deficient. Always clear supplements with your rheumatologist or pharmacist, as kidney, lung, or esophageal involvement—and the drugs used to treat them—can change what is safe for you.

What are the new treatments for scleroderma?

Two medicines are now FDA-approved to slow lung damage in systemic sclerosis: nintedanib (approved 2019) and tocilizumab (approved 2021). Beyond these, several therapies are showing benefit in late-stage studies—B-cell depletion with rituximab, T-cell modulation with abatacept, JAK inhibitors, cannabinoid-mimetic lenabasum, and autologous stem-cell transplant—so a rheumatologist may discuss clinical-trial or specialty-center referral if standard drugs are not enough.

How debilitating is scleroderma?

Scleroderma ranges from localized skin thickening that is more of a nuisance to a systemic form that can stiffen joints, cause painful Raynaud’s attacks, and—if it scars the lungs, heart or kidneys—significantly cut stamina or even shorten life; fortunately, only a subset of patients develop these severe complications. Thanks to earlier diagnosis, blood-pressure drugs that prevent kidney crisis, medications that slow lung scarring, and physical/occupational therapy, most people now remain independent and 10-year survival is roughly 75–85 %, so close monitoring with a rheumatologist is key to limiting how debilitating the disease becomes.

Does walking help scleroderma?

Yes—done correctly, regular walking can help many people with scleroderma by improving blood flow to the fingers and toes, keeping joints and skin less stiff, and boosting heart-lung fitness and energy levels; small studies even show gains in grip strength and walking distance after supervised programs. Start with short, comfortable walks (5-10 minutes) on level ground, dress warmly to protect against Raynaud’s, use well-fitting shoes if you have foot ulcers, and have your doctor or physiotherapist adjust the plan if you have lung involvement or pulmonary hypertension. Think of walking as one part of an overall movement routine—aim for about 150 minutes a week of gentle activity, adding stretching or hand exercises—as tolerated and monitored by your care team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security